42
Participants
Start Date
January 26, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
T3011
T3011 will be given intratumorally， Q2W；
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
Chengdu Shangjin Nanfu Hospital, Chengdu
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
The Third People's Hospital of Zhengzhou, Zhengzhou
RECRUITING
Sun Yat-sen University Cancer Center, Zhongshan
Shanghai Pharmaceuticals Holding Co., Ltd
INDUSTRY